Ease Regulations For Affordable Biosimilars, Groups Urge
This article was originally published in PharmAsia News
Present biosimilar guidelines pose regulatory barriers to the launch of affordable medicines and are guided by transnational companies, claim leading civil society groups. They are calling for a review of international regulations that can facilitate the launch of lower-priced biotherapeutics.
You may also be interested in...
Brand and generic drug companies continued their debate on distinguishable INNs for biosimilars during a Federal Trade Commission meeting Feb. 4.
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.